This study ( NCT01622790 ) evaluated , first , the bioequivalence ( BE ) of a fixed-dose combination ( FDC ) tablet containing dolutegravir 50 mg , abacavir 600 mg , and lamivudine 300 mg ( dolutegravir/abacavir/lamivudine FDC ) vs coadministered dolutegravir 50 mg and abacavir/lamivudine combination tablets ( Epzicom ) and , second , the effect of food on the dolutegravir/abacavir/lamivudine FDC tablet .